Mymetics Secures New Patent for Virosome based Vaccines

Epalinges, Switzerland, 29 November 2010

Mymetics Corporation (OTCBB: MYMX), a pioneer in the development of vaccines preventing early transmission of human infectious diseases, announced today that the United States Patent and Trademark Office has issued a notice of allowance for the patent application "Phospholipid Virosome" # 10/544,939, based on WO 04/071492.

Media Name Media Type Description Download
Mymetics Secures New Patent for Virosome based Vaccines PDF Download